Immuneering (IMRX) Operating Expenses (2020 - 2026)

Immuneering's Operating Expenses history runs 7 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 0.97% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $59.2 million (down 7.79% YoY), while the FY2025 annual figure was $59.4 million, down 7.33% from the prior year.
• Operating Expenses was $15.3 million for Q1 2026 at Immuneering, up from $13.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $18.6 million in Q4 2024 to a low of $11.7 million in Q2 2022.
• Historically, Operating Expenses has averaged $14.7 million across 5 years, with a median of $14.8 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 98.0% in 2022, then fell 25.89% in 2025.
• A 5-year view of Operating Expenses shows it stood at $14.0 million in 2022, then rose by 16.56% to $16.3 million in 2023, then grew by 13.84% to $18.6 million in 2024, then fell by 25.89% to $13.8 million in 2025, then gained by 11.51% to $15.3 million in 2026.
• The last three Operating Expenses figures came in at $15.3 million (Q1 2026), $13.8 million (Q4 2025), and $15.4 million (Q3 2025), per Business Quant data.